Core Insights - Labcorp reported a strong performance in 2025 with over 7% revenue growth, 13% adjusted EPS growth, and margin expansion of more than 50 basis points [3][5] - The company highlighted a robust pipeline for mergers and acquisitions (M&A) and a backlog of $8.7 billion in Biopharma Laboratory Services (BLS) [4][11] Financial Performance - Fourth-quarter revenue reached $3.5 billion, up 5.6% year over year, driven by organic growth of 3.8%, acquisitions contributing 1.2%, and foreign currency translation of 0.6% [8] - Adjusted EPS for the fourth quarter was $4.07, reflecting an 18% increase year over year [9] - Free cash flow for the quarter was $490 million, down from $665 million, primarily due to working capital timing [9] Growth Strategy - The company launched over 130 new tests in 2025, focusing on oncology, women's health, neurology, and autoimmune diseases [6][7] - Labcorp's OnDemand service expanded to offer tests for over 200 biomarkers, including food allergies and thyroid health [7] - Management emphasized technology and AI initiatives to enhance efficiency and customer experience, including AI-driven tools for scheduling and reporting [7] M&A Activity - In the fourth quarter, Labcorp completed several acquisitions, including outreach laboratory services from Parkview Health and anatomic pathology assets from Incyte Diagnostics [2] - The company signed or closed 13 deals, contributing over $1 billion in revenue growth over the past three years [2] 2026 Guidance - Labcorp forecasts enterprise revenue growth of 4.7% to 6% for 2026, with adjusted EPS expected to be between $17.65 and $18.25, implying about 9% growth at the midpoint [5][15] - Diagnostics revenue is projected to rise 5% to 6%, with half of the growth expected from volume and half from price/mix [13] - BLS revenue is anticipated to grow 3% to 5%, with Central Labs expected to grow mid-single digits organically [14] Operational Highlights - Diagnostics revenue was $2.7 billion, up 5.5%, with organic growth of 4.1% and acquisitions contributing 1.5% [10] - BLS revenue was $793 million, up 3.4%, with Central Labs revenue growing 11.1% [11] - The company reported a book-to-bill ratio of 1.16 for the quarter, indicating strong demand in Central Labs [12] Leadership Changes - Labcorp announced the upcoming retirement of key executives, with successors appointed under a succession plan [21]